UQCRC2抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-5: Jurkat, Raji, hepg2, A431 and HT-29 cell, Primary antibody: P08954(UQCRC2 Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P08954(UQCRC2 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P08954(UQCRC2 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The UQCRC2 antibody targets the Ubiquinol-Cytochrome c Reductase Core Protein 2 (UQCRC2), a key subunit of mitochondrial Complex III (cytochrome bc1 complex) in the electron transport chain (ETC). UQCRC2 is essential for oxidative phosphorylation, stabilizing the complex's structure and facilitating electron transfer from ubiquinol to cytochrome c, which drives ATP synthesis. Mutations in the UQCRC2 gene are linked to mitochondrial disorders, neurodegenerative diseases, and cancer, highlighting its role in cellular energy metabolism and disease pathology.

UQCRC2 antibodies are widely used in research to study mitochondrial function, protein expression, and localization via techniques like Western blotting, immunohistochemistry, and immunofluorescence. They help investigate metabolic reprogramming in cancer, mitochondrial dysfunction in neurodegeneration, and responses to oxidative stress. Commercial UQCRC2 antibodies are typically raised in rabbits or mice using recombinant protein fragments or synthetic peptides. Validation includes testing specificity in knockout models or siRNA-treated cells. Researchers rely on these antibodies to explore UQCRC2’s interactions within Complex III, its post-translational modifications, and its potential as a therapeutic target in mitochondrial-related diseases.